Peter Stein

Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by¹³C Nuclear Magnetic Resonance Spectroscopy

Gerald I. Shulman, Douglas L. Rothman, Thomas Jue et al. · New England Journal of Medicine · 1990 · 1.2K citations · Full text

Life Sciences, Endocrinology, Physiology +15

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Kjeld Hermansen, Mark Kipnes, Edmund Luo et al. · Diabetes Obesity and Metabolism · 2007 · 526 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics · 2006 · 516 citations

Medicine, Pharmacology, Pharmacotherapy +15

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Bruce Neal, Vlado Perkovic, Dick de Zeeuw et al. · American Heart Journal · 2013 · 338 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

Russell Scott, Mei Wu, Miguel A. Sánchez et al. · International Journal of Clinical Practice · 2006 · 260 citations

Pharmacy, Pharmacology, Pharmacotherapy +11